At December 31, 2022, the Company held cash, cash equivalents and investments of C$32.4M. "This was a transformative quarter for Reunion. We enter 2023 well positioned with both encouraging clinical data and a highly experienced executive leadership team in place to execute on our mission to rapidly and efficiently develop RE104 as a potential therapeutic option for the millions of patients underserved by today’s standard of care in depression and other mental health disorders," said Greg Mayes, President and CEO, Reunion. "We recently announced our first ever clinical data where RE104 showed encouraging pharmacokinetic, pharmacodynamic and safety data. The analysis included a dose that demonstrated the short-duration and robust pharmacodynamic effects we believe are needed for clinical efficacy in Phase 2. We also welcomed Dr. Robert Alexander as Chief Medical Officer, an accomplished pharmaceutical executive who brings to Reunion a proven track record in psychopharmacology. We remain on track to share the results of our Phase 1 study with the FDA in preparation for Phase 2 development in postpartum depression later this year."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REUN:
- Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
- Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET
- Reunion Neuroscience appoints Robert Alexander, M.D as CMO
- Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer
- Reunion completes interim data analysis for Phase 1 trial with RE104